KONEXBiotech & Pharma236340

Medizen Humancare

₩1,170▼ 0.85%2026-11-18 close
Market Cap
₩3.6B
Turnover
₩1,170
Volume
1 shares
Shares out.
3.1M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Overseas B2B Push Amid Capital Impairment

Medizen Humancare is widening its genomic testing business through overseas hospital channels, but a negative total equity position is the central variable in assessing the company.

  1. 1

    The AGM result filing dated March 31, 2026 lists 2025 standalone revenue of 4,423, an operating loss of 1,158 and net income of 324 (apparently in KRW millions).

  2. 2

    The same filing shows total assets of 3,189, total liabilities of 15,665 and total equity of negative 12,475, which indicates capital impairment.

  3. 3

    The company signed a testing supply contract with Indonesian hospitals in June 2026 and an agreement with a Vietnamese healthcare firm in October 2026.

  4. 4

    In Korea, the Ministry of Health and Welfare has been expanding the list of direct-to-consumer (DTC) genetic test items, and the company competes with players such as Macrogen.

  5. 5

    With a market capitalization of KRW 4.1 billion and turnover of KRW 1,943,539, the thin liquidity typical of KONEX underlies price volatility.

02

Business structure

Medizen Humancare was incorporated in July 2012, launched its disease-prediction genomic analysis system M-CHECK, and listed on KONEX on January 26, 2016. The company's website describes it as a research-driven firm specializing in individual disease-prediction genomic analysis.

A 2018 Meritz Securities report showed M-CHECK at 98.2% of 2017 revenue. That implies a business that depends almost entirely on a single service. M-CHECK earns revenue through DTC genetic tests and business-to-business (B2B) testing services.

According to a 2020 Korea Investment & Securities company report, two large health-screening centers accounted for 50-60% of sales. How that customer concentration has changed since then could not be confirmed. Overseas, the company completed the establishment of its Indonesian joint venture, PT.

IndoMedizen Sehat, in November 2020. The joint venture serves as the base for local hospital channels. The company's annual report also outlines a plan to develop and commercialize epigenome-based disease-prediction tests to strengthen its position in precision medicine.

On competition, TheVC lists Macrogen, Geninus and GC Genome as comparable companies. In February 2024, Hankyung reported that Medizen Humancare was among ten companies certified for DTC genetic testing in Korea.

However, comparable figures on revenue scale and market share against peers could not be confirmed from the filings.

03

Recent trends

At the annual general meeting on March 31, 2026, the approval of the 14th-term financial statements passed with 100% approval of the voting shares exercised. The standalone summary in the AGM result filing lists revenue of 4,423, an operating loss of 1,158 and net income of 324.

The unit appears to be KRW millions, which is consistent with the KRW 4.42 billion revenue figure compiled by Saramin. Net income is shown as positive despite the operating loss, and the cause could not be confirmed.

The same filing shows total assets of 3,189, total liabilities of 15,665, total equity of negative 12,475 and capital stock of 1,507. According to TheVC, the current ratio fell from 21.7% in 2023 to 16.1% in 2024 and recovered slightly to 16.8% in 2025.

On the business side, the company announced on June 2, 2026 that its Indonesian joint venture had signed a disease-prediction genetic testing supply contract with local medical institutions.

On October 3 and 4, 2026, it signed a multi-omics healthcare agreement with Longevity Medical System in Hanoi and Ho Chi Minh City. The filing list also shows a litigation-related filing on February 4, 2026 and an investor relations briefing result on May 11, 2026.

The counterparty and the claim amount of the lawsuit could not be confirmed. On the share price, the stock closed at KRW 1,863 on March 31, 2026, up 15.00% from the prior day. Per Investing.com, the price was KRW 2,100 on October 1, 2026, and the 52-week range is KRW 1,300 to KRW 4,015.

The October 27, 2026 price of KRW 1,350 (+3.85% day over day) sits near the 52-week low, and neither filings nor press reports explain the move over this stretch.

04

Outlook

The key near-term question is whether the overseas contracts translate into actual test volumes and revenue. Under the Indonesian hospital contract, test analysis is performed jointly by the Jakarta laboratory and the company's headquarters laboratory in Korea.

This structure could increase both the load on the headquarters laboratory and the role of the local joint venture. The specific service scope and business model of the Vietnam agreement are to be set through further discussions. Contract values and expected volumes have not been disclosed for either deal.

In Korea, Dailypharm reported that the Ministry of Health and Welfare expanded the DTC genetic test list to 181 items and revised its certification guidelines. Rules on secondary services that use test results are also being eased.

However, the same report said the government is concerned about indiscriminate use of test results. In February 2024, Hankyung estimated that the global DTC genetic testing market would grow from USD 1.715 billion in 2022 to USD 7.191 billion by 2030.

That is a market estimate and does not guarantee results for any individual company. Indicators to watch include the size of operating losses in later reporting periods, any capital-raising disclosures and the progress of the lawsuit.

05

Bull factors

Expanding overseas hospital channels

In June 2026, the company signed a disease-prediction genetic testing supply contract with local hospitals through its Indonesian joint venture. In October 2026, it signed a multi-omics agreement with a Vietnamese healthcare company. These deals could diversify revenue and reduce reliance on domestic screening centers. However, contract values are undisclosed, so their contribution is hard to gauge.

Certification and accumulated test data

The company was listed among the ten DTC genetic testing companies certified in Korea. In April 2022, Research Alum put the cumulative number of tests at about 700,000. Research Alum assessed that this data could become a foundation for drug development and personalized medicine. The current cumulative test count and any data sales results could not be confirmed.

Shifting domestic regulation

The Ministry of Health and Welfare expanded the DTC genetic test list to 181 items. Rules linking test results to products and services are also being relaxed. In 2022, Research Alum judged that the company could benefit from DTC deregulation. That was a brokerage view at the time, and whether it showed up in revenue needs to be checked separately.

06

Bear factors

Negative total equity

On a 2025 standalone basis, total liabilities of 15,665 far exceed total assets of 3,189, and total equity is negative 12,475. Accumulated deficits exceed capital stock of 1,507, so how operations are financed matters. The current ratio of 16.8% also leaves limited short-term payment capacity. Any future capital increase or debt restructuring could affect existing shareholders' stakes.

Operating losses and price competition

A 2025 standalone operating loss of 1,158 shows that profitability in the core business has not yet been secured. In 2020, Korea Investment & Securities pointed out that price competition over screening-institution contracts had lowered per-test prices. Competition with larger peers such as Macrogen continues. It is also unclear whether customer concentration remains high, which adds uncertainty.

Thin trading liquidity

The market capitalization is KRW 4.1 billion and the day's turnover is KRW 1,943,539. When trading is thin, even small orders can move quotes sharply. The 52-week range of KRW 1,300 to KRW 4,015 is consistent with this characteristic. Execution can be difficult, so trading at a desired time and price may not be possible.

07

Risk factors

Macro

The Southeast Asian business in Indonesia and Vietnam is exposed to local economic conditions and exchange-rate swings. Overseas hospital channels can make results volatile depending on collection and the timing of contract performance. The interest-rate environment also affects financing costs for a company with impaired capital.

Industry and regulation

The Ministry of Health and Welfare expressed concern about indiscriminate use of DTC test results and urged testing institutions to take responsibility and exercise care. The pace and scope of deregulation could change with policy direction. Genomic information is also sensitive in terms of personal data protection and cross-border data transfers.

Company and market

With total equity shown at negative 12,475, tighter financing conditions could strain operations. The filing list includes a litigation-related filing on February 4, 2026, but its contents and outcome could not be confirmed. Low liquidity on KONEX and limited disclosure also raise uncertainty in judging the stock.

08

Overall view

Medizen Humancare is a small KONEX-listed company that started with a single-minded focus on genomic testing and is now extending hospital channels into Indonesia and Vietnam.

On a 2025 standalone basis, it runs a business with revenue of 4,423, yet it recorded an operating loss of 1,158 and total equity of negative 12,475. The bullish case rests on overseas contracts, its certified-provider status and the easing of DTC regulation in Korea.

The bearish case rests on capital impairment, continued operating losses and thin trading liquidity. The size and volume of the overseas contracts, the substance of the lawsuit and any capital-raising plan remain unconfirmed variables. This report is for information only, and the judgment is left to the reader.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. m.news.nate.com
  2. kind.krx.co.kr
  3. m.irgo.co.kr
  4. medizencare.com
  5. venturesquare.net
  6. biotimes.co.kr
  7. prestocknews.com
  8. home.imeritz.com
  9. thevc.kr
  10. investing.com
  11. m.dailypharm.com
  12. hankyung.com
  13. fnnews.com
  14. m.saramin.co.kr

Report written 2026-10-27 · Data as of 2026-10-26

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis